Skip to main content
Explore Health Topics
Heart Health Diabetes Women's Health Pregnancy Digestive Health Mental Health
Medical Guides → • Calculators →
✨ Unlock your Free Personal Health Dashboard — smart guidance tailored to your age & vitals
🩺 Kidney Urology

Vanrafia (Atrasentan) Once-Daily Tablet for IgA Nephropathy: Proteinuria Drop, Ankle Edema & Pregnancy Precautions

Dr. Priya Sammani (MBBS)

Medically reviewed by Dr. Priya Sammani (MBBS) — Updated on Nov 21, 2026 · 16 min read

Vanrafia (Atrasentan) Once-Daily Tablet for IgA Nephropathy: Proteinuria Drop, Ankle Edema & Pregnancy Precautions
Table of Contents ▾

If your nephrologist has recently recommended Vanrafia (atrasentan) for IgA nephropathy (IgAN), one of the very first things you are probably looking up is what Vanrafia side effects actually feel like day to day — especially ankle swelling, fluid retention, mild drops in hemoglobin, and strict pregnancy precautions. Because IgA nephropathy is most often diagnosed in young and middle-aged adults who work, exercise, travel, or hope to start a family, having a once-daily, steroid-free tablet that directly calms glomerular injury without suppressing your immune system is a major clinical milestone.

As doctors, we emphasize that understanding why atrasentan works the way it does takes the mystery — and much of the anxiety — out of starting therapy. Unlike systemic corticosteroids that carry weight gain, mood changes, glucose spikes, and infection risks, Vanrafia is a highly selective Endothelin Type A (ETA) receptor antagonist taken right alongside your existing blood pressure kidney shield (an ACE inhibitor or ARB, and often an SGLT2 inhibitor). Below is a complete, practical guide covering the Phase 3 ALIGN trial results, how much proteinuria drops, how to manage ankle edema and hemodilution safely at home, liver and drug-interaction checks, and essential family-planning rules.

Key Takeaways on Vanrafia (Atrasentan) for IgA Nephropathy

  • Targeted Non-Steroid Kidney Protection: Vanrafia (atrasentan 0.75 mg once daily) selectively blocks Endothelin-1 at the ETA receptor (>1,800-fold selectivity over ETB), calming mesangial cell proliferation, glomerular inflammation, podocyte stress, and fibrosis without systemic immunosuppression.
  • Proven 36%+ Proteinuria Drop & 2.5-Year eGFR Preservation: In the Phase 3 ALIGN trial (NEJM 2025; final 2.5-year Lancet 2026 results), adding atrasentan to maximally tolerated ACEi/ARB therapy cut 24-hour urine protein-to-creatinine ratio (UPCR) by 36.1% versus placebo by Week 36 and significantly slowed long-term eGFR decline.
  • Added On Top of Your ACEi/ARB (and SGLT2 Inhibitor): Unlike sparsentan (which replaces your ACEi or ARB), Vanrafia is added directly onto your current RAS blocker — and pairing it with an SGLT2 inhibitor delivers ~36%–37% additional proteinuria reduction while helping offset fluid retention.
  • Manageable Fluid Retention & Dilutional Anemia: The most common Vanrafia side effects are mild-to-moderate peripheral ankle swelling and a small, non-toxic dip in hemoglobin (~0.5–0.8 g/dL) caused by mild plasma dilution rather than bone marrow damage or bleeding.
  • Strict Pregnancy Boxed Warning (No Liver REMS Required): Vanrafia carries a Boxed Warning for embryo-fetal toxicity — requiring negative baseline pregnancy testing and effective contraception during therapy and for 2 weeks after stopping — while requiring baseline liver bloodwork without a restrictive liver REMS registry.
⚡ Interactive Clinical Tool
🤰
Pregnancy Due Date Calculator (EDD)

Free pregnancy due date calculator. Enter your last period date or conception date to find your EDD, current trimester, and key milestones.

Open Interactive Calculator →

What Is Vanrafia (Atrasentan) and How Does It Protect Kidneys in IgA Nephropathy?

Vanrafia (atrasentan) is a once-daily oral, highly selective Endothelin Type A (ETA) receptor antagonist approved to reduce proteinuria and protect kidney function in adults with primary IgA nephropathy at risk of rapid disease progression, taken as an add-on to maximally tolerated RAS-inhibitor therapy.

To understand why blocking ETA receptors is so effective, it helps to look inside the kidney's microscopic filtering units (glomeruli). In IgA nephropathy, galactose-deficient IgA1 immune complexes settle inside the glomerular mesangium — the structural support core between filtering capillaries. Once trapped there, those immune complexes trigger local surges of a potent signaling peptide called Endothelin-1 (ET-1).

Inside the human kidney, ET-1 binds to two very different receptors with opposite jobs:

  • ETA Receptors (The Injury Pathway): Overactivation of ETA receptors constricts glomerular blood vessels, raises internal filtering pressure, stimulates abnormal mesangial cell proliferation, strips away delicate podocyte foot processes (allowing protein and red blood cells to leak into the urine), and activates pro-inflammatory and fibrotic gene pathways (Kuo et al., 2026).
  • ETB Receptors (The Protective Clearing Pathway): ETB receptors release nitric oxide and prostacyclin to relax blood vessels, clear excess ET-1 from circulation, and promote healthy sodium excretion.

Because atrasentan is more than 1,800 times more selective for ETA than ETB, it shuts down the destructive ETA cascade while leaving the beneficial ETB clearing pathway intact. As translational kidney transcription data in Kidney360 (Kuo et al., 2026) demonstrated, atrasentan directly downregulates mesangial proliferation, inflammatory signaling, and fibrotic remodeling genes inside glomeruli — addressing not just filtration pressure, but the cellular tissue injury driving IgAN progression.

Clinical Trial Evidence: How Much Does Vanrafia Lower Proteinuria and Slow eGFR Loss?

For decades, we doctors had limited options when a patient's urine protein stayed above 0.75–1.0 g/day despite maximum tolerated doses of lisinopril, ramipril, losartan, irbesartan, or telmisartan. The global randomized, double-blind, placebo-controlled Phase 3 ALIGN trial changed that standard of care:

  • Rapid, Deep Proteinuria Reduction (ALIGN 36-Week Results — NEJM 2025): Among adults with biopsy-proven IgA nephropathy and baseline proteinuria of at least 1 g/day despite optimized ACEi/ARB therapy, atrasentan 0.75 mg once daily produced a 36.1% placebo-adjusted reduction in 24-hour UPCR at Week 36 (-38.1% from baseline with atrasentan vs -3.1% with placebo; P < 0.0001), with measurable reductions starting by Week 6 (Heerspink et al., 2025).
  • Confirmed Long-Term Kidney Function Protection (ALIGN Final 2.5-Year Results — Lancet 2026): In the final 136-week (2.5-year) readout of ALIGN, atrasentan sustained proteinuria lowering and demonstrated statistically significant preservation of chronic and total eGFR slope compared with placebo, confirming that early proteinuria reduction translates into real slowing of kidney function loss (Heerspink et al., 2026).
  • Powerful Combination With SGLT2 Inhibitors (JASN 2026): Many modern IgAN patients already take dapagliflozin or empagliflozin. Both the dedicated placebo-controlled crossover trial in JASN (Heerspink et al., 2026) and the SGLT2-inhibitor stratum of ALIGN confirmed that adding atrasentan on top of RAS blockade plus an SGLT2 inhibitor delivers an additional ~36%–37% drop in proteinuria — while SGLT2-driven gentle sodium/water excretion helps keep fluid retention low.

How Vanrafia Compares With Other Modern IgA Nephropathy Treatments

Patients often ask how Vanrafia fits alongside other recently approved IgAN therapies reviewed across modern clinical trial landscapes (Gholizadeh Ghozloujeh et al., 2025). Here is a practical two-column comparison:

Therapy / Drug Class How It Works Alongside Your Regimen & Key Practical Differences
Vanrafia (Atrasentan 0.75 mg once daily)
Selective ETA Receptor Antagonist
Added ON TOP of your existing ACEi or ARB (no washout required) and pairs seamlessly with SGLT2 inhibitors. Non-immunosuppressive; fixed 0.75 mg tablet with no dose titration; no mandatory FDA liver REMS registry (routine baseline liver labs still checked); main class monitoring is fluid retention, mild hemodilution, and pregnancy prevention.
Filspari (Sparsentan 200–400 mg once daily)
Dual ETA + Angiotensin II (AT1) Receptor Blocker
Replaces your existing ACEi or ARB because an ARB-like AT1 blocker is already built into the molecule (never combine with another ACEi/ARB!). Requires dose titration from 200 mg to 400 mg, periodic liver enzyme monitoring, and strict pregnancy prevention.
SGLT2 Inhibitors (Dapagliflozin / Empagliflozin)
Proximal Tubule Glucose-Sodium Blockers
Lower intraglomerular pressure via tubuloglomerular feedback and provide mild osmotic diuresis. Frequently used together with Vanrafia + ACEi/ARB because their gentle fluid-offloading effect counterbalances ETA-related sodium retention.
Targeted-Release Budesonide (Tarpeyo) / Complement Blockers (Iptacopan)
Mucosal Gut-IgA1 or Alternative Complement Pathway
Target upstream immune complex production in Peyer's patches or glomerular C3 complement inflammation. Because they act on immune pathways while Vanrafia protects glomerular vascular/mesangial cells downstream, nephrologists tailor sequencing or combinations to biopsy activity and infection risk.

Vanrafia Side Effects Explained: Fluid Retention, Hemoglobin Dip, Blood Pressure & Liver Checks

When patients search for Vanrafia side effects, the clinical trial numbers are reassuring: overall discontinuation rates due to adverse events in ALIGN were low and very close to placebo. However, knowing the four physiologic class effects of ETA blockade lets you and your kidney team prevent minor symptoms from ever becoming disruptive.

Vanrafia Side Effect & Mechanism What to Expect & Step-by-Step Clinical Management
1. Fluid Retention & Ankle Edema (~11%–17%)
Collecting-duct sodium and water retention from renal tubular ETA blockade
Usually appears within the first 2 to 6 weeks as mild sock-line indentations around the ankles by evening or a sudden 2–3 lb scale jump. Managed effectively with a <2,000 mg/day low-sodium diet, concurrent SGLT2 inhibitor use, or adding/adjusting a low-dose loop or thiazide diuretic (such as furosemide or torsemide) without stopping Vanrafia. Patients with severe pre-existing NYHA Class III–IV heart failure require extra caution.
2. Mild Drop in Hemoglobin / Anemia (~6%–9%)
Hemodilution from slight plasma volume expansion
Average hemoglobin drops by ~0.5 to 0.8 g/dL during the first 4–8 weeks and then plateaus. Crucial pearl: This is water dilution of your bloodstream — not iron loss, internal bleeding, or bone marrow suppression! Your doctor will check a baseline CBC and recheck at 1–3 months, especially if your starting hemoglobin is below 10 g/dL.
3. Mild Low Blood Pressure / Lightheadedness (~4%–7%)
Smooth-muscle relaxation of systemic blood vessels
Systolic and diastolic blood pressure typically dip by ~3–4 mmHg. In most IgAN patients with high blood pressure, this is an added cardiovascular bonus; if your baseline BP is already near 95–100/60 mmHg, stand up slowly from bed and ask your nephrologist whether another BP pill should be trimmed slightly.
4. Nasal Congestion & Liver Enzyme Monitoring
Mucosal vasodilation & hepatic metabolism safety
Mild stuffy nose or upper respiratory symptoms can occur from harmless nasal blood-vessel relaxation (use saline spray — never take oral decongestants like pseudoephedrine or NSAIDs!). Serious liver enzyme spikes (>3× ULN) were rare (~2%, similar to placebo) in ALIGN, so no REMS registry is required, but baseline ALT, AST, and bilirubin are checked before starting and repeated if clinically indicated.

Step-by-Step Home Fluid & Weight Action Plan for the First 8 Weeks

As doctors, we find that a simple 60-second morning routine during your first two months on Vanrafia catches fluid retention early, long before your ankles feel tight or your breathing feels heavy:

  1. Weigh Yourself Every Morning Under Identical Conditions: Step on the same digital scale right after emptying your bladder and before eating breakfast or getting dressed. Jot the number down or log it on your phone.
  2. Know Your Two "Call the Clinic" Weight Thresholds: Contact your nephrology clinic promptly (non-emergently, if you feel fine breathing) if your morning weight climbs by 3 lb (1.4 kg) or more in 24–48 hours, or 5 lb (2.3 kg) or more over 7 days, or if gentle thumb pressure over your shin leaves a pit lasting several seconds.
  3. Keep Daily Sodium Below 2,000 mg (About 5 g of Table Salt): Endothelin-related fluid retention is strongly salt-sensitive. Cutting restaurant broth soups, processed deli meats, soy sauce, instant noodles, and salted snacks dramatically reduces ankle swelling on atrasentan.
  4. Never Stop Your Diuretic or SGLT2 Inhibitor Without Asking: If your nephrologist prescribed a low-dose water pill or an SGLT2 inhibitor alongside Vanrafia, keep taking it consistently — they work as partners.

Boxed Warning: Pregnancy, Contraception, Breastfeeding & Male Fertility Considerations

Because IgA nephropathy frequently affects women and men in their 20s, 30s, and early 40s, reproductive counseling is a mandatory part of starting any endothelin receptor antagonist:

  • Why Vanrafia Is Strictly Contraindicated in Pregnancy (Boxed Warning): Endothelin-1 signaling at ETA receptors is essential during early embryonic development to guide neural crest cells that form the baby's heart, great vessels, jaw, and skull. Taking atrasentan during pregnancy carries a high risk of severe congenital birth defects and pregnancy loss.
  • Before Starting & During Therapy (Patients Who Can Become Pregnant): You must have a documented negative pregnancy test prior to your first tablet and use highly effective contraception throughout treatment and for at least 2 weeks after your final dose (atrasentan's elimination half-life is ~24 hours, so 2 weeks allows complete washout). If you miss a period or suspect pregnancy, pause Vanrafia and call your nephrologist immediately.
  • Planning a Future Pregnancy Safely: Needing Vanrafia now does not mean you can never have children! In fact, lowering heavy proteinuria and stabilizing your eGFR first often puts your kidneys in a much safer position for a planned future pregnancy. Simply talk to your nephrologist months ahead so Vanrafia (and your ACEi/ARB/SGLT2i) can be safely washed out at least 2 weeks prior to conception and transitioned to pregnancy-safe kidney blood pressure medications.
  • Breastfeeding & Male Sperm Count Note: Because atrasentan passed into milk in animal studies with potential infant adverse effects, breastfeeding is not advised during therapy. For men planning fatherhood, endothelin receptor antagonists as a class can cause reversible decreases in sperm count in a subset of patients — mention any upcoming fertility plans to your nephrologist upfront.

How to Take Vanrafia Correctly & Crucial Drug Interactions to Avoid

Getting the full kidney-protective benefit from Vanrafia comes down to straightforward daily habits and avoiding two major enzyme/transporter clashes:

  • Standard Dose: Take one 0.75 mg tablet once daily at roughly the same time each day, with or without food.
  • Swallow Whole & Keep in Original Bottle: Do not cut, crush, or chew Vanrafia tablets. Store tablets in their original tightly closed container with the desiccant packet inside (do not move a month's worth into an unsealed humid bathroom pillbox unless directed by your pharmacist, as atrasentan tablets are moisture-sensitive).
  • Missed Dose Rule: If you miss a dose, skip it and take your next scheduled tablet at your usual time the next day — never take two tablets at once.
  • Key Drug Interactions (OATP1B1/1B3 & CYP3A): Atrasentan enters liver cells for clearance via OATP1B1 and OATP1B3 transporters and is metabolized partly by CYP3A. Concomitant use with strong or moderate OATP1B1/1B3 inhibitors (such as cyclosporine or acute rifampin) is avoided because it causes large spikes in atrasentan blood levels and fluid retention. Conversely, strong CYP3A inducers (chronic rifampin, carbamazepine, phenytoin, or herbal St. John's Wort) slash atrasentan levels and blunt kidney protection.

Practical Dos and Don'ts While Taking Vanrafia (Atrasentan)

Smart Habits to Follow (Dos):

  • Do check your morning weight daily for the first 6–8 weeks and keep daily dietary sodium under 2,000 mg to prevent ankle swelling.
  • Do complete your baseline blood tests before starting — including a pregnancy test (if applicable), liver panel (ALT, AST, bilirubin), hemoglobin/CBC, eGFR, and potassium.
  • Do keep taking your prescribed ACE inhibitor or ARB (unless your nephrologist explicitly changes it) — Vanrafia was proven as an add-on partner, not a standalone replacement.
  • Do tell every doctor, dentist, and pharmacist that you take atrasentan before starting new antibiotics, antifungals, immunosuppressants (especially cyclosporine), or herbal supplements.

Mistakes to Avoid (Don'ts):

  • Don't take over-the-counter NSAID painkillers (ibuprofen, naproxen, diclofenac, celecoxib) or oral nasal decongestants (pseudoephedrine) — NSAIDs worsen kidney filtration and trap fluid, while decongestants raise glomerular blood pressure.
  • Don't split, crush, chew, or store tablets loose in damp bathrooms — keep Vanrafia in its original desiccant-protected bottle.
  • Don't stop contraception early — continue reliable birth control during treatment and for a full 14 days after your last dose.

When to Seek Immediate Emergency Care (Call 911 / 999 / 112)

Most side effects on Vanrafia are mild and handled with a quick call to your nephrology clinic. However, go to the nearest emergency department or call 911 (US/Canada), 999 (UK), or 112 (EU/International) immediately if you develop any of the following red-flag symptoms:

  • Acute shortness of breath, trouble breathing when lying flat (orthopnea), waking up gasping for air, or coughing up frothy sputum: Urgent warning signs of pulmonary fluid overload or acute heart failure decompensation.
  • Rapid, severe generalized swelling spreading from your feet and calves into your thighs, abdomen, or face over 24–48 hours alongside chest tightness.
  • Signs of acute liver injury: Yellowing of your eyes or skin (jaundice), dark tea-colored urine unrelated to a typical IgAN flare, persistent right-upper-abdominal pain, severe nausea/vomiting, or unexplained fever and extreme fatigue.
  • Fainting (syncope), chest pain, or severe dizziness where you cannot stand safely.

The Take-Home Message

In IgA nephropathy, every gram of protein kept out of your urine today translates into years of preserved kidney function tomorrow. Vanrafia (atrasentan 0.75 mg once daily) gives adults with persistent proteinuria a targeted, non-steroid way to cut protein leakage by more than a third and slow long-term eGFR loss right on top of standard RAS and SGLT2-inhibitor therapy. By pairing daily low-sodium habits and quick morning weight checks with baseline liver bloodwork and reliable contraception when applicable, the vast majority of patients tolerate Vanrafia smoothly and stay active while protecting their kidneys for the long run.

❓ FAQ

Frequently Asked Medical Questions (FAQ)

Evidence-based clinical answers to common patient questions

How quickly does Vanrafia (atrasentan) start lowering urine protein in IgA nephropathy?

In the Phase 3 ALIGN clinical trial, measurable reductions in 24-hour urine protein-to-creatinine ratio (UPCR) were already seen by Week 6 of once-daily 0.75 mg atrasentan therapy, reaching a 36.1% placebo-adjusted reduction by Week 36 and maintaining durable proteinuria and eGFR protection through 2.5 years of follow-up.

Does Vanrafia cause weight gain, and is it fat gain or water weight?

Unlike steroid medications (such as prednisone or budesonide), Vanrafia does not increase appetite, blood sugar, or body fat. Any rapid 2–5 pound rise on the scale in the first few weeks of Vanrafia is mild sodium-and-water fluid retention from ET-A receptor blockade, which responds well to a low-sodium diet (<2,000 mg/day), SGLT2 inhibitor co-therapy, or a low-dose diuretic prescribed by your nephrologist.

Why did my hemoglobin drop slightly after starting Vanrafia?

A small decrease in hemoglobin of roughly 0.5 to 0.8 g/dL in the first 1 to 2 months is a well-known class effect called hemodilution — mild fluid retention slightly increases the liquid plasma portion of your blood, making red blood cell concentration look slightly lower on paper without destroying red blood cells or harming bone marrow. Levels typically stabilize after Week 8–12.

Do I have to stop my ACE inhibitor, ARB, or Farxiga/Jardiance to start Vanrafia?

No! Unlike sparsentan (Filspari), which contains a built-in angiotensin receptor blocker and therefore requires stopping your ACE inhibitor or ARB first, Vanrafia blocks only the ET-A receptor and is specifically designed to be added on top of your maximally tolerated ACE inhibitor or ARB — and clinical trials confirm it works safely and effectively alongside SGLT2 inhibitors like dapagliflozin or empagliflozin.

Does Vanrafia require enrollment in a mandatory FDA Liver REMS program?

No. Because liver enzyme elevations in the Phase 3 ALIGN trial were uncommon (~2%) and similar to placebo, Vanrafia was approved without a restrictive liver REMS registry. Your nephrologist will still check a baseline liver panel (ALT, AST, and bilirubin) before starting treatment and repeat liver tests if clinically needed or if you have symptoms.

📚

Verified Scientific & Medical References (PubMed / WHO)

✓ Peer-Reviewed Sources
📚 Cite This Medical Article (Vancouver / APA 7th / HTML Link) ▾
Vancouver (ICMJE): Sammani P. Vanrafia (Atrasentan) Once-Daily Tablet for IgA Nephropathy: Proteinuria Drop, Ankle Edema & Pregnancy Precautions [Internet]. Nirogi Lanka Medical Encyclopedia; Nov 21, 2026. Available from: https://nirogilanka.com/en/vanrafia-atrasentan-iga-nephropathy-fluid-retention-care/
APA 7th: Sammani, P. (Sat ). Vanrafia (Atrasentan) Once-Daily Tablet for IgA Nephropathy: Proteinuria Drop, Ankle Edema & Pregnancy Precautions. Nirogi Lanka. https://nirogilanka.com/en/vanrafia-atrasentan-iga-nephropathy-fluid-retention-care/
<a href="https://nirogilanka.com/en/vanrafia-atrasentan-iga-nephropathy-fluid-retention-care/" target="_blank" rel="noopener">Vanrafia (Atrasentan) Once-Daily Tablet for IgA Nephropathy: Proteinuria Drop, Ankle Edema & Pregnancy Precautions — Nirogi Lanka</a>
🔍 Search Keywords: vanrafia side effects • vanrafia atrasentan iga nephropathy fluid retention care • vanrafia atrasentan iga nephropathy fluid retention care symptoms • vanrafia atrasentan iga nephropathy fluid retention care causes and treatment • Vanrafia (Atrasentan) Once-Daily Tablet for IgA Nephropathy: Proteinuria Drop, Ankle Edema & Pregnancy Precautions
💬 Patient Questions & Comments (0)

Have a question or experience to share? Post a comment or reply to other readers below.

🛡️ Plain Text Only • No Links
👤

No comments yet. Be the first to share your question or experience below.

🩺 Articles For You
Tukysa (Tucatinib) Regimen in HER2-Positive Breast Cancer & Brain Metastases: Proactive Diarrhea & Liver Management
Scemblix (Asciminib) STAMP Inhibitor for Chronic Myeloid Leukemia (CML): The 3-Hour Fasting Window & Pancreatic Checks
Aphonia (Complete Loss of Voice): Causes, Symptoms, and How to Recover
XYYYY Syndrome, XYYY & XYY Syndrome: What Extra Y Chromosomes Mean, Symptoms & Support
Dayvigo Side Effects: Lemborexant Dosage, How Fast It Works, and Safety Guide
Eosinophilia: What High Eosinophils Mean in Your Blood Test (Causes, Levels & Next Steps)
⚠️ Important: Medical articles and information on Nirogi Lanka are strictly for educational and awareness purposes and do not substitute professional medical advice, diagnosis, or treatment. Always consult a qualified physician for any medical concerns.